References
- 1. Ferreira, CR. The burden of rare diseases. Am J Med Genet. 2019;179A:885-92.10.1002/ajmg.a.61124
- 2. Wakap SN, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165-73.10.1038/s41431-019-0508-0
- 3. Kumar P, Radhakrishnan J, Chowdhary MA, Giampietro PF. Prevalence and patterns of presentation of genetic disorders in a pediatric emergency department. Mayo Clin Proc. 2001;76(8):777-83.10.1016/S0025-6196(11)63220-5
- 4. Kirk EP, Barlow-Stewar K, Selvanathan A, Josephi-Taylor S, Worgan L, Rajagopalan S et al. Beyond the panel: preconception screening in consanguineous couples using the TruSight One “clinical exome”. Genet Med. 2019;21(3):608–12.10.1038/s41436-018-0082-929961766
- 5. Fareeda M, Afzala M. Genetics of consanguinity and inbreeding in health and disease. Ann Hum Biol. 2017;44(2):99-107.10.1080/03014460.2016.126514827892699
- 6. Bell CJ, Dinwiddie DL, Miller NA, Hateley SL, Ganusova EE, Mudge J et al. Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med. 2011 Jan 12;3(65):65ra4.10.1126/scitranslmed.3001756374011621228398
- 7. Antonarakis, SE. Carrier screening for recessive disorders. Nat Rev Genet. 2019;20(9):549-61.10.1038/s41576-019-0134-231142809
- 8. Henneman L, Borry P, Chokoshvili D, Cornel CC, van El CG, Forzano F et al. Responsible implementation of expanded carrier screening. Eur J Hum Genet. 2016;24(6):e1 e12.10.1038/ejhg.2015.271486746426980105
- 9. Miller KE, Hoyt R, Rust S, Doerschuk R, Huang Y, Lin SM. The financial impact of genetic diseases in a pediatric accountable care organization. Public Health Front. 2020;8(58).10.3389/fpubh.2020.00058705930532181236
- 10. ACOG Committee opinion No. 691 Summary: Carrier Screening for Genetic Conditions. Obstetrics & Gynecology. 2017;129(3):597-9.10.1097/AOG.000000000000194828225421
- 11. van der Hout S, Dondorp W, de Wert G. The aims of expanded universal carrier screening: Autonomy, prevention, and responsible parenthood. Bioethics. 2019;33(5):568–76.10.1111/bioe.12555659408830734373
- 12. Mehta N, Lazarin GA, Spiegel E, Berentsen K, Brennan K, Giordano J et al. Tay-Sachs Carrier Screening by Enzyme and Molecular Analyses in the New York City Minority Population. Genet Test Mol Biomark 2016;20(9):504-9.10.1089/gtmb.2015.0302531472327362553
- 13. van der Hout S, Holtkamp K, Henneman L, de Wert G, Dondorp W. Advantages of expanded universal carrier screening: what is at stake? Eur J Hum Genet. 2016;25(1):17-21.10.1038/ejhg.2016.125515976127677414
- 14. Muncie HL, Campbell JS. Alpha and beta thalassemia. Am Fam Physician. 2009;80(4):339-44.
- 15. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5(1):1-15.10.1186/1750-1172-5-11289311720492708
- 16. Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB. Carrier screening for Beta-thalassaemia: a review of international practice. Eur J Hum Genet. 2010;18(10):1077-83.10.1038/ejhg.2010.90298745220571509
- 17. Kalokairinou EM. The experience of ß-thalassemia and its prevention in Cyprus. Med Law. 2007;26:291-307.
- 18. ACOG Committee. Practice bulletin No 78. Haemoglobinopathies in pregnancies. Obstet Gynecol. 2007;109(1):229-37.10.1097/00006250-200701000-00055
- 19. Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB. Carrier screening for Beta-thalassaemia: a review of international practice. Eur J Hum Genet. 2010;18(10):1077-83.10.1038/ejhg.2010.90
- 20. Cao A, Galanello FR, Melis MA, Angius A, Ximenes A, Rosatelli A et al. Prevention of Homozygous /8-Thalassemia by Carrier Screening and Prenatal Diagnosis in Sardinia. Am J Hum Genet. 1981;33(4):592.
- 21. Cao A. Carrier screening and genetic counselling in β-thalassemia. Int J Hematol. 2002;76(2):105-13.10.1007/BF0316509812430909
- 22. Holtkamp KCA. Henneman L, Gillie JJP, Meijers-Heijboer H, Cornel MC, Lakeman P. Direct-to-consumer carrier screening for cystic fibrosis via a hospital website: a 6 year evaluation. J. Community Genet. 2018;10(2):249-57.10.1007/s12687-018-0388-y
- 23. Castellani C, Macek Jr M, Cassiman JJ, Duff A, Massie J, ten KateLP et al. Benchmarks for Cystic Fibrosis carrier screening: A European consensus document. J Cyst Fibros. 2010;9(3):165-78.10.1016/j.jcf.2010.02.00520363197
- 24. Doksum T, Bernhardt BA, Holtzman NA. Carrier Screening for Cystic Fibrosis among Maryland Obstetricians before and after the 1997 NIH Consensus Conference. 5(2):111-6.10.1089/10906570175314556511551096
- 25. Ioannou L, McClaren BJ, Massie J, Lewis S, Metcalfe SA, Forrest L et al. Population-based carrier screening for cystic fibrosis: a systematic review of 23 years of research. Genet. Med. 2014;16(3):207-16.10.1038/gim.2013.125
- 26. Rowe CA, Wright CF. Expanded universal carrier screening and its implementation within a publicly funded healthcare service. J Community Genet. 2020;11(1):21-38.10.1007/s12687-019-00443-6696240531828606
- 27. Wapner RJ. A case for improved carrier screening. Contemporary ob/gyn. 2020;64(9):31-35.
- 28. Cecchi AC, Vengoechea ES, Kaseniit KE, Hardy MW, Kiger LA, Mehta N et al. Screening for Tay-Sachs disease carriers by full-exon sequencing with novel variant interpretation outperforms enzyme testing in a pan-ethnic cohort. Mol Genet Genomic Med. 2019;7(8):e836.10.1002/mgg3.836668786031293106
- 29. Lazarin GA, Haque IS, Nazareth S, Iori K, Patterson AS, Jacobson AL et al. An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals. Genet Med. 2013;15(3): 178-86.10.1038/gim.2012.114390855122975760
- 30. Evolving Science of Genetic Carrier Screening. AJMC Perspectives. 2018
- 31. Grody WW, Thompson BH, Gregg AR, Bean LH, Monaghan KG, Schneider A et al. ACMG position statementon prenatal/preconception expanded carrier screening. Genet Med. 2013;15(6):482-3.10.1038/gim.2013.4723619275
- 32. Srinivasan BS, Evans EA, Flannick J, Patterson AS, Chang CC, Pham T et al. Reproductive biomedicine online. 2010;21(4):537-51.10.1016/j.rbmo.2010.05.012
- 33. Azimi M, Schmaus K, Greger V, Neitzel D, Rochelle R, Dinh T. Carrier screening by next-generation sequencing: health benefits and cost effectiveness. Mol Genet Genomic Med. 2016;4(3):292-302.10.1002/mgg3.204486756327247957
- 34. Di Resta C, Galbiati S, Carrera P, Ferrari M. Next-generation sequencing approach for the diagnosis of human diseases: open challenges and new opportunities. 2018;29(1): 4-14.
- 35. Haque IS, Lazarin GA, Kang HP, Evans EA, Goldberg JD, Wapner JD. Modeled Fetal Risk of Genetic Diseases Identified by Expanded Carrier Screening. JAMA. 2016;316(7):734-42.10.1001/jama.2016.1113927533158
- 36. Holtkamp CA, Mathijssen IB, Lakeman P, van Maarle M, Dondorp WJ, Henneman L et al. Factors for successful implementation-based expanded carrier screening: learning from existing initiatives. Eur. J. Public Health. 2016;27(2):372-7.10.1093/eurpub/ckw110
- 37. Ben-Shachar R, Svenson A, Goldberg JD, Muzzey D. A data-driven evaluation of the size and content of expanded carrier screening panel. Genet Med. 2019;21(9):1931-9.10.1038/s41436-019-0466-5675231130816298
- 38. Lazarin GA, Hawthorne F, Collins NS, Platt EA, Evans EA, Haque IS. Systematic Classification of Disease Severity for Evaluation of Expanded Carrier Screening Panels. PLoS One, 2014;9(12):e114391.10.1371/journal.pone.0114391426239325494330
- 39. Platinga M, Birnie E, Abbott KM, Sinke RJ, Lucassen AM, Schuurmans M et al. Population-based preconception carrier screening: how potential users from the general population view a test for 50 serious diseases. Eur J Hum Genet. 2016;24(10):1417-23.10.1038/ejhg.2016.43502768827165008
- 40. Bell CJ, Dinwiddle DL, Miller NA, Hateley SL, Ganusova EE, Mudge J et al. Carrier Testing for Severe Childhood Recessive Diseases by Next-Generation Sequencing. Sci Transl Med. 2011;3(65):65ra4-65ra4.10.1126/scitranslmed.3001756374011621228398
- 41. Beachuamp KA, Muzzey D, Wong KK, Hogan GJ, Karimi K, Candille SI et al. Systematic design and comparison of expanded carrier screening. Genet Med. 2018;20(1):55-63.10.1038/gim.2017.69576315428640244
- 42. Wienke S, Brown K, Farmer M, Strange C. Expanded carrier screening panels-does bigger mean better? J Community Genet. 2014;5(2):191-8.10.1007/s12687-013-0169-6395546024062228
- 43. Dungan J. Expanded carrier screening: what the reproductive endocrinologist needs to know. Fertil Steril. 2019;109(2):183-9.10.1016/j.fertnstert.2017.11.03029447660
- 44. Prior TW. Next-generation carrier screening: are we ready? Genome Med. 2014;6(8):1-3.10.1186/s13073-014-0062-x425443625473430
- 45. Platinga M, Birnie E, Schuurmans J, Buitenhuis AH, Boersma E, Lucassen AM et al. Expanded carrier screening for autosomal recessive conditions in health care: Arguments for a couple-based approach and examination of couples’ views. Prenat Diagn. 2018;39(5):369-78.10.1002/pd.5437659398630756401
- 46. Capalbo A, Valero RA, Jimenez-Almanaz J, Pardo PM, Fabiani M, Jimenez D et al. Optimizing clinical exome design and parallel gene-testing for recessive genetic conditions in preconception carrier screening: Translational research genomic data from 14,125 exomes. PLoS Genet. 2019;15(10):e1008409.10.1371/journal.pgen.1008409679723531589614
- 47. Rose NC, Wick M. Current recommendations: Screening for Mendelian disorders. Semin Perinatol. 2016;40(1):23-8.10.1053/j.semperi.2015.11.00426706396
- 48. Schuurmans J, Birnie E, van den Heuvel LM, Platinga M, Lucassen A, van der Kolk DM et al. Feasibility of couple-based carrier screening offered by general practitioners. Eur J Hum Genet. 2019;27(5):691-700.10.1038/s41431-019-0351-3646200830742054
- 49. Leung ML, McAdoo S, Watson D, Stumm K, Harr M, Wang Xiang et al. A transparent approach to calculate detection rate and residual risk for carrier screening. J Mol Diagn. 2021;23(1):91-102.10.1016/j.jmoldx.2020.10.00933349347
- 50. Lazarin GA, Haque IS. Expanded carrier screening: A review of early implementation and literature. Semin Perinatol 2016;40(1):29-34.10.1053/j.semperi.2015.11.00526718446
- 51. Fridman H, Behar DM, Carmi S, Levy-Lahad E. Preconception carrier screening yield: effect of variants of unknown significance in partners of carriers with clinically significant variants. Genet Med. 2020;22(3): 646-53.10.1038/s41436-019-0676-x31624327
- 52. Xi Y, Chen G, Lei C, Wu J, Zhang S, Xiao M et al. Expanded carrier screening in Chinese patients seeking the help of assisted reproductive technology. Mol Genet Genomic Med. 2020;8:e1340.10.1002/mgg3.1340750741132573981
- 53. Edwards JG, Feldman G, Goldberg J, Gregg AR, Norton ME, Rose NC et al. Expanded carrier screening in reproductive medicine—points to consider: a joint statement of the American College of Medical Genetics and Genomics, American College of Obstetricians and Gynecologists, National Society of Genetic Counselors, Perinatal Quality Foundation, and Society for Maternal-Fetal Medicine. Obstet Gynecol. 2015;125(3):653-62.10.1097/AOG.000000000000066625730230
- 54. Abacan M, Alsubaie L, Borlow-Stewart K, Caanen B, Cordier C, Courtney E et al. The Global State of the Genetic Counseling Profession. Eur J Hum Genet. 2019;27(2):183-97.10.1038/s41431-018-0252-x633687130291341
- 55. Fakih A, Spector-Bagdady K. Should clinicians leave “expanded” carrier screening decisions to patients? AMA J Ethics. 2019;21(10):E858.10.1001/amajethics.2019.858698838631651385
- 56. Cho D, McGowan ML, Metcalfe J, Sharp RR. Expanded carrier screening in reproductive healthcare: perspectives from genetics professionals. Hum. Reprod. 2013;28(6):1725-30.10.1093/humrep/det091
- 57. Kraft SA, Duenas D, Wilfond BS, Goddard KAB. The evolving landscape of expanded carrier screening: challenges and opportunities. Genet. Med. 2019;21(4):790-7.10.1038/s41436-018-0273-4